About
ErlySign develops a saliva-based, non-invasive diagnostic test that detects oral cancer early and provides results within about 15 minutes. The company is conducting clinical trials and partnering with oncology centers in India while advancing biomarker research for multi-cancer detection.
Explore ErlySign's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.